Navigation Links
Aperion Biologics Reaches Midpoint of Enrollment in Z-Lig™ Anterior Cruciate Ligament Reconstruction Medical Device Performance Trial
Date:9/14/2011

SAN ANTONIO, Texas, Sept. 14, 2011 /PRNewswire/ -- Aperion Biologics, Inc. announced that it has reached the midpoint of patient enrollment and implantation in the Company's clinical trial of its Z-Lig™ Anterior Cruciate Ligament Reconstruction (ACLR) Device for the treatment of ligament injuries of the knee. The randomized multicenter study commenced in January 2011 in both Europe and South Africa to provide safety and performance data in the reconstruction of patients' knees with primary ACL ruptures. The 60-patient study results will be used to support regulatory commercialization approvals and clinical acceptance of the Z-Lig ACLR device in select markets outside of the United States.

Martin Lind, M.D., Ph.D., Head of the Division of Sportstraumatology, Department of Orthopedics, Aarhus University Hospital in Denmark said, "Anterior cruciate ligament (ACL) injuries are one of the most frequent problems we encounter as orthopaedic surgeons, and the enrollment rate of patients into the study reflects this demand. A strong factor for our participation in this clinical evaluation was the potential for the Z-Lig as the first biologic graft option for ligament reconstruction procedures not produced from human tissue. The Z-Lig has the potential to be a game-changer as we evaluate its clinical utility and performance."

"Successful enrollment in the Z-Lig ACLR multi-national clinical trial is a vital step towards our goal of commercialization. These data, together with our continued ISO 13485 certification and validation activities, position the company for a CE Mark application and commercial introduction of the Z-Lig in the first half of 2012," said Daniel R. Lee, Aperion Biologics' CEO.

The ACL is the most commonly injured knee ligament. Over 800,000 knee ligament reconstruction surgeries are estimated to be performed each year worldwide. Further information on the Z-Lig study is available on w
'/>"/>

SOURCE Aperion Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aperion Biologics Initiates Clinical Trial of Z-Lig™ Device for Anterior Cruciate Ligament Reconstruction
2. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
3. Dr. Lester Mandelker to Collaborate with Nuovo Biologics, LLC
4. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
5. New Conference Offers Solutions for Success in the Growing Biologics Market
6. CMC Biologics Expands Its Production Facility and Rebrands Its Corporate Identity
7. Oncobiologics, Inc. to Unveil New Biologics Proof-of-Concept Engine at BIO International Convention
8. Crescendo Biologics Appoints Matthew Roe as Chief Business Officer
9. Bacterin International Signs Its Second National GPO Contract for Bacterin Biologics and Its First For Wound Drains with ROi
10. Reportlinker Adds Whats Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015
11. Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... its newly developed Bruton,s tyrosine kinase (BTK) inhibitor ... The results of these preclinical evaluations have been ... The feedback received from the Agency is supportive ... Additional preclinical work is required to begin a ...
(Date:2/27/2015)... Scotia (PRWEB) February 27, 2015 ... vaccine and immunotherapy company, today announced that the ... application for Fast Track designation and Phase I ... in conjunction with the mutual co-development agreement signed ... obtained Fast Track designation for the DPX-Survivac. , ...
(Date:2/27/2015)... Feb. 27, 2015  Pfenex Inc. (NYSE MKT: PFNX), ... biosimilar therapeutics, today announced that it will be presenting ... on March 2 nd at 3pm PST. Patrick Lucy, ... panel discussing the current state of the biosimilar industry ... For more information on CALBIO 2015 ...
(Date:2/27/2015)...  Steep Hill, the industry leader in cannabis testing ... open a full service medical cannabis quality assurance laboratory ... advanced scientific tools and methodology to the state, for ... currently the only laboratory licensed by the New Mexico ... in order to meet the recently adopted regulatory requirements ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2
... Detection Marker Technology Now ... Applied to Universal Technique, BAGNOLS-SUR-CEZE, ... and a developer and marketer of diagnostic,assays for the quantification ... ELISA diagnostic tool, Chromoa. This ELISA kit,complements CISBIO,s existing chromogranin ...
... Study Also Shows 82% of Women Do Not ... RED BANK, N.J., Sept. 23 According to a ... (NWHRC), the,nation,s leading source for women,s health information, women ... less,likely to be up to date with preventive screenings, ...
... WASHINGTON, Sept. 23 AHIC Successor, Inc. today,announced ... formation of its,Board of Directors is an important ... partnership. The new organization is being,established in cooperation ... (HHS), as a successor to the American Health ...
Cached Biology Technology:CISBIO Bioassays Launches Chromoa(TM) Chromogranin A ELISA Kit 2Video: Women Unsatisfied With Body and Breasts, Less Likely to Comply With Screenings, Including Mammography 2Video: Women Unsatisfied With Body and Breasts, Less Likely to Comply With Screenings, Including Mammography 3AHIC Successor, Inc. Announces Board of Directors 2AHIC Successor, Inc. Announces Board of Directors 3AHIC Successor, Inc. Announces Board of Directors 4
(Date:2/5/2015)... JOLLA, Calif. , Jan. 30, 2015  It ... the great power and potential for genomic science as ... aid in disease prevention and treatment.  I was honored ... potential new, government-funded precision medicine program. ... advancing the science of genomics—from the first sequenced genome ...
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ... its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . ... of production capacity to meet customer demand. ... - http://photos.prnewswire.com/prnh/20150113/168790 Invented ...
(Date:1/22/2015)... and POINT ROBERTS, Washington , ... source covering leading sectors including technology and tech stocks, releases ... marketplace featuring master pickpocket and security consultant Apollo Robbins ... stolen and talks about the Wocket™ biometric smart wallet, a ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... / b3c newswire / - Critical Outcome ... today from animal experiments carried out at a prominent ... adds to the already impressive data package for COTI-2, ... with first line therapies with low toxicity in seven ...
... of cancer mortality in children. Even if a cure ... stressful treatment which can be harmful to the developing ... gentle treatment methods. The most important childhood brain tumors ... young patients each year in Germany, and pylocytic astrocytoma, ...
... This release is available in Spanish . ... understand the trophic food chains involving microbian plankton. That is, to ... that live organisms can be classified from the perspective of nutrition. ... these levels are united one to the other, forming a chain. ...
Cached Biology News:ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 3ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 4Germany starts its part in the International Cancer Genome Project 2Germany starts its part in the International Cancer Genome Project 3Germany starts its part in the International Cancer Genome Project 4University of the Basque Country research on plankton at Urdaibai 2
... The Corning CellBIND surface is produced by ... more hydrophilic surface giving more consistent, even ... CellBIND enhances cell attachment and growth uunder ... medium. • CellBIND may provide a more ...
Automated Cell Culture Flask...
... 100-240 V, uses xMAP technology for simultaneous ... and peptides in one microplate well. The ... 100 color-coded bead sets, each of which ... (enzyme substrates, receptors, antigens, or antibodies) specific ...
Cell Culture Flask, 75 cm, treated polystyrene...
Biology Products: